Vitiligo is a chronic skin condition in which patches of skin lose their pigment because the cells that produce melanin are destroyed. The patches can appear anywhere on the body, tend to grow over time, and are more noticeable on darker skin. Its exact cause is not fully understood, though it is widely regarded as an autoimmune condition, sometimes occurring alongside other autoimmune diseases.
Facts
Classification
ICD-10 ChapterXII: Diseases of the Skin and Subcutaneous Tissue 1 Communicable or Non-communicable Transmission Route Causative Agent
Causative Agent (category) First Described Connections
Associated With
Skin depigmentation disorder; dermatology specialty.
Treated By
Source PUVA therapy (Wikipedia)
Sources
1. Wikipedia: ICD-10
WikipediaList of chapters, Chapter XIIQuote, List of chapters, Chapter XII
Diseases of the skin and subcutaneous tissue
View the Source 2. Wikipedia: Vitiligo
Wikipedia- Vitiligo ( VIT-ih-LY-goh) is a chronic autoimmune disorder that causes skin to lose pigment (specifically melanin, which gives the skin color) in patches that vary in size and can appear anywhere...
History section
Descriptions of a disease believed to be vitiligo date back to a passage in the Ebers Papyrus (c. 1500 BC), an ancient Egyptian medical text.
Lead section, disease-category statement
Vitiligo ( VIT-ih-LY-goh) is a chronic autoimmune disorder that causes skin to lose pigment (specifically melanin, which gives the skin color) in patches that vary in size and can appear anywhere on the body.
Lead section, transmission-route statement
Vitiligo ( VIT-ih-LY-goh) is a chronic autoimmune disorder that causes skin to lose pigment (specifically melanin, which gives the skin color) in patches that vary in size and can appear anywhere on the body.
View the Source PUVA therapy (Wikipedia)
Treated By: PUVA Therapy, Lead: treats VitiligoQuote, Treated By: PUVA Therapy, Lead: treats Vitiligo
PUVA (psoralen and UVA) is an ultraviolet light therapy treatment for skin diseases: vitiligo, eczema, psoriasis, graft-versus-host disease, mycosis fungoides, large plaque parapsoriasis, and cutaneous T-cell lymphoma, using the sensitizing effects of the drug psoralen.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.